An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection (NCT05202366) | Clinical Trial Compass
CompletedNot Applicable
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
United States15 participantsStarted 2022-02-08
Plain-language summary
The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s).
This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations.
Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female ≥18 (and ≤99) at the time of Informed Consent.
✓. Nail fungal infection of at least one great toe \[per visual assessment by the clinical investigator\]
✓. Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator.
✓. Subject must be physically able to reach toes to clean them and apply product.
✓. Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study.
✓. Subject is willing and available to return for study follow up.
✓. Signed written informed consent form (ICF) prior to any trial related activity (subjects must have the mental, literate, and legal ability to give a written informed consent, which must comply with the ICH GCP guidelines and local requirements.
✓. Agree to take and share pictures of the treated toenails on a periodic basis during the study and follow-up period.
Exclusion criteria
What they're measuring
1
Investigator Global Assessment (IGA) of affected toenails
✕. Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.
✕. Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Product (i.e., essential oils, fragrance, choline, phosphatidylcholine, propylene glycol, limonene, cellulose).
✕. Nails with clinical evidence of no or low distal growth.
✕. History or presence of another skin/nail condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).
✕. Basal cell carcinoma within 6 months of Visit 1.
✕. Uncontrolled systemic disease.
✕. Foreseen unprotected and intense/excessive UV exposure during the course of the study.
✕. Use of prohibited concomitant medications/procedures, as specified below in Table 2, during the study or within the defined washout periods.